Image Source: CNBC
CVS stock surged after CVS Health announced plans to split into two separately traded public companies by the first half of 2028. The dramatic restructuring would separate the company’s roughly 9,000 retail pharmacies from its insurance business and pharmacy benefit manager, Caremark.
The announcement represents a major reversal for one of the healthcare industry’s most vertically integrated companies. CVS Health spent years building a broad healthcare platform designed to connect pharmacies, insurance, prescription benefits and primary care under one corporate structure.
CVS Stock Rallies as Healthcare Giant Unveils Historic Breakup
CVS Health said the planned separation followed a comprehensive strategic review by its board of directors. Both businesses would become publicly traded companies, while existing shareholders would receive ownership in each entity.
The insurance and pharmacy benefit management company would retain the CVS Health name and be led by CEO David Joyner. The retail pharmacy company would be called CVS Pharmacy and led by Prem Shah, currently group president of CVS Health. The company said additional leadership appointments and board members would be announced later.
“From a position of strength, and a focus on the long term, we plan to create two focused companies to improve consumer engagement, affordability, and care coordination,” Joyner said in the company’s announcement.
Why CVS Health Is Reversing Its Aetna Strategy
The breakup would effectively unwind CVS Health’s $78 billion acquisition of Aetna, completed in 2018. That deal transformed CVS from a pharmacy-focused retailer into a healthcare conglomerate combining insurance coverage, drug benefits, pharmacies and medical services.
Under the proposed structure, CVS Health would group Aetna and Caremark with Oak Street Health, Signify Health and the company’s specialty drug business. CVS Pharmacy would operate as a more focused retail and prescription-dispensing company.
The move comes as CVS works through an aggressive turnaround plan under Joyner, who became CEO in October 2024. The program includes approximately $2 billion in cost reductions, store closures, leadership changes and efforts to control Medicare Advantage expenses.
Despite the surprise announcement, CVS stock has gained roughly 70% since Joyner took the top job. That rise has pushed CVS Health’s market value to approximately $117 billion, according to the company’s latest figures.
Strong Revenue Base Could Support Two New Companies
CVS Health’s divisions each represent substantial businesses. The pharmacy segment generated $37.66 billion in sales during 2025, while the insurance unit reported $36.29 billion in revenue. The healthcare services segment produced $51.24 billion.
Separating those operations could allow each company to develop a more focused strategy, improve efficiency and invest in technology tailored to its customers. CVS Health said the split may also improve consumer engagement, affordability and care coordination.
For investors, the key question is whether the combined businesses can create more value independently than they did under one corporate umbrella. Retail pharmacies face pressure from changing consumer habits, reimbursement challenges and competition from major chains and online providers. The insurance and PBM businesses face their own cost, regulatory and political pressures.
PBM Scrutiny Adds Urgency to CVS Breakup
The proposed separation also arrives as pharmacy benefit managers face growing bipartisan scrutiny in Washington and across state governments. PBMs negotiate drug prices and manage prescription benefits for insurers and employers, but critics have raised concerns about opaque pricing, market concentration and conflicts of interest.
Those concerns can become more complicated when a single company owns an insurer, a PBM and a large pharmacy network. Congress enacted PBM reforms in February, including changes to how PBMs are compensated under Medicare Part D. Several states have also moved to restrict or examine PBM ownership of pharmacies.
Leerink Partners analyst Michael Cherny described the planned breakup as a complete shock but noted that CVS’s retail pharmacy operation has been performing well. The business has reportedly gained market share from competitors, while gross margins have stabilized through CostVantage, a pharmacy reimbursement model introduced by CVS.
Cherny said a standalone retail pharmacy company may now have a stronger outlook than it did during CVS’s earlier strategic review. He also suggested that reducing vertical integration could help address relentless state legislative scrutiny.
What the CVS Stock Split Means for Investors
- Existing CVS shareholders are expected to own shares in both new public companies.
- The CVS Health name will remain with the insurance and PBM business.
- CVS Pharmacy will operate as the standalone retail pharmacy company.
- The separation is targeted for completion by the first half of 2028.
- Regulatory review, execution risks and market conditions could affect the timeline.
The transaction is not yet complete, and CVS Health still faces several years of operational planning before the separation. Investors will likely focus on financial disclosures, leadership appointments, debt allocation and the long-term prospects of each business.
FAQs About CVS Stock and the Breakup
Why is CVS Health splitting into two companies?
CVS Health says the separation will create two more focused businesses, improve efficiency, support innovation and strengthen consumer engagement. The plan also addresses concerns surrounding vertical integration.
What companies will CVS Health create?
The insurance and PBM operations will retain the CVS Health name. The retail pharmacy operations will become CVS Pharmacy. Existing shareholders are expected to own shares in both companies.
When will the CVS breakup happen?
CVS Health is targeting completion during the first half of 2028, although the final timing may depend on regulatory, financial and operational requirements.
Who will lead the two companies?
David Joyner will lead the CVS Health insurance and PBM company. Prem Shah will lead CVS Pharmacy. Additional leadership details are expected later.
How has CVS stock performed recently?
CVS stock has risen roughly 70% since David Joyner became CEO in October 2024, bringing CVS Health’s market value to approximately $117 billion.
